Zacks: Analysts Expect Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) to Post -$2.58 Earnings Per Share

Equities research analysts predict that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will announce earnings per share (EPS) of ($2.58) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. The lowest EPS estimate is ($3.40) and the highest is ($1.75). Tonix Pharmaceuticals posted earnings per share of ($61.00) during the same quarter last year, which suggests a positive year-over-year growth rate of 95.8%. The firm is expected to issue its next earnings results on Monday, March 16th.

According to Zacks, analysts expect that Tonix Pharmaceuticals will report full-year earnings of ($20.79) per share for the current fiscal year, with EPS estimates ranging from ($24.48) to ($17.09). For the next year, analysts anticipate that the firm will report earnings of ($4.04) per share, with EPS estimates ranging from ($5.98) to ($2.10). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Tonix Pharmaceuticals.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Friday, November 8th. The company reported ($5.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.35) by ($1.34).

A number of research analysts recently issued reports on the company. ValuEngine lowered Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Roth Capital lowered their target price on Tonix Pharmaceuticals from $4.00 to $1.30 and set a “buy” rating on the stock in a report on Friday, August 30th.

NASDAQ:TNXP opened at $0.86 on Friday. The business’s 50-day moving average price is $1.49 and its 200 day moving average price is $1.01. The firm has a market cap of $5.61 million, a P/E ratio of 0.00 and a beta of 1.03. Tonix Pharmaceuticals has a 52-week low of $0.88 and a 52-week high of $42.00. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 0.01.

A number of large investors have recently added to or reduced their stakes in TNXP. Vanguard Group Inc. acquired a new position in Tonix Pharmaceuticals during the second quarter worth about $117,000. Acadian Asset Management LLC grew its holdings in Tonix Pharmaceuticals by 620.0% during the second quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock worth $89,000 after acquiring an additional 56,516 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in Tonix Pharmaceuticals during the second quarter worth about $42,000. 35.56% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.

Recommended Story: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Tonix Pharmaceuticals (TNXP)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit